Combination Therapy of Imiquimod 5%Cream and Cryotherapy vs Monotherapy for Common Warts:Randomized Comparative Trial.

NCT ID: NCT06973473

Last Updated: 2025-05-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-07-01

Study Completion Date

2026-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the clinical efficacy and safety of topical imiquimod 5% cream combined with cryotherapy versus either of theme alone for the treatment of common warts by clinical and dermoscopic assessments.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Topical Imiquimod 5% cream Combined with Cryotherapy Versus either of them alone in Treatment of Common Warts: A prospective Randomized Comparative Trial

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Warts

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with common warts diagnosed clinically and by dermoscopy.
* Patients older than 18years old.

Exclusion Criteria

* Pregnancy and lactation.
* Immunosuppression or being under any kind of treatment causing
* absolute or relative immunosuppression.
* Patients with chronic systemic diseases.
* All cases of bleeding tendency or using anticoagulants.
* Concurrent use of systemic or topical treatments of warts in the last 4 weeks.
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Doaa yahia mohamed hassan

candidate

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Eman Fathy Ahmed Lecturer of Dermatology, Venereology and Andrology Faculty of

Role: CONTACT

00201002258614

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Treatment of common warts

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.